Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

TNFRSF17 (TNF Receptor Superfamily Member 17)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

TNFRSF17 expression	Multiple Myeloma	TNFRSF17 expression	Multiple Myeloma	belantamab mafodotin-blmf Sensitive: B - Late Trials belantamab mafodotin-blmf Sensitive : B	belantamab mafodotin-blmf Sensitive: B - Late Trials belantamab mafodotin-blmf Sensitive : B
TNFRSF17-L	Multiple Myeloma	TNFRSF17-L	Multiple Myeloma	AMG 701 Sensitive: C3 – Early Trials AMG 701 Sensitive : C3	AMG 701 Sensitive: C3 – Early Trials AMG 701 Sensitive : C3
TNFRSF17 overexpression	Multiple Myeloma	TNFRSF17 overexpression	Multiple Myeloma	ciltacabtagene autoleucel Sensitive: C3 – Early Trials ciltacabtagene autoleucel Sensitive : C3	ciltacabtagene autoleucel Sensitive: C3 – Early Trials ciltacabtagene autoleucel Sensitive : C3
TNFRSF17 deletion	Multiple Myeloma	TNFRSF17 deletion	Multiple Myeloma	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
TNFRSF17 elevation + Chr t(14;16)	Multiple Myeloma	TNFRSF17 elevation + Chr t(14;16)	Multiple Myeloma	ruxolitinib Resistant: C3 – Early Trials ruxolitinib Resistant : C3	ruxolitinib Resistant: C3 – Early Trials ruxolitinib Resistant : C3
TNFRSF17 amplification	Multiple Myeloma	TNFRSF17 amplification	Multiple Myeloma	elranatamab-bcmm Resistant: C3 – Early Trials elranatamab-bcmm Resistant : C3	elranatamab-bcmm Resistant: C3 – Early Trials elranatamab-bcmm Resistant : C3
CD19 expression + TNFRSF17 expression	Diffuse Large B Cell Lymphoma	CD19 expression + TNFRSF17 expression	Diffuse Large B Cell Lymphoma	AZD0120 Sensitive: C3 – Early Trials AZD0120 Sensitive : C3	AZD0120 Sensitive: C3 – Early Trials AZD0120 Sensitive : C3
TNFRSF17 deletion	Multiple Myeloma	TNFRSF17 deletion	Multiple Myeloma	idecabtagene vicleucel Resistant: C4 – Case Studies idecabtagene vicleucel Resistant : C4	idecabtagene vicleucel Resistant: C4 – Case Studies idecabtagene vicleucel Resistant : C4
TNFRSF17 positive	Multiple Myeloma	TNFRSF17 positive	Multiple Myeloma	teclistamab-cqyv Sensitive: D – Preclinical teclistamab-cqyv Sensitive : D	teclistamab-cqyv Sensitive: D – Preclinical teclistamab-cqyv Sensitive : D
TNFRSF17 underexpression	Multiple Myeloma	TNFRSF17 underexpression	Multiple Myeloma	CTX-8573 Sensitive: D – Preclinical CTX-8573 Sensitive : D	CTX-8573 Sensitive: D – Preclinical CTX-8573 Sensitive : D
TNFRSF17 expression	Multiple Myeloma	TNFRSF17 expression	Multiple Myeloma	ACLX-001 Sensitive: D – Preclinical ACLX-001 Sensitive : D	ACLX-001 Sensitive: D – Preclinical ACLX-001 Sensitive : D
TNFRSF17 expression	Multiple Myeloma	TNFRSF17 expression	Multiple Myeloma	CC-93269 + CC-220 Sensitive: D – Preclinical CC-93269 + CC-220 Sensitive : D	CC-93269 + CC-220 Sensitive: D – Preclinical CC-93269 + CC-220 Sensitive : D